U.S. Glucagon Delivery Devices Market (2024 - 2030) Size, Share & Trends Analysis Report By Device Type (Injectable, Intranasal), By Distribution Channel (Retail Pharmacies, Online Pharmacies), By End-use, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Device Type
                        1.2.2. Distribution Channel
                        1.2.3. End Use
                        1.2.4. Regional scope
                        1.2.5. Estimates and forecasts timeline
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                        1.4.5. Details of primary research
                            1.4.5.1. Data for primary interviews in North America
                            1.4.5.2. Data for primary interviews in Europe
                            1.4.5.3. Data for primary interviews in Asia Pacific
                            1.4.5.4. Data for primary interviews in Latin America
                            1.4.5.5. Data for Primary interviews in MEA
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity flow analysis (Model 1)
                        1.7.2. Approach 1: Commodity flow approach
                        1.7.3. Volume price analysis (Model 2)
                        1.7.4. Approach 2: Volume price analysis
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                        2.2.1. Device type outlook
                        2.2.2. Distribution channel outlook
                        2.2.3. End use outlook
                        2.2.4. Regional outlook
                    2.3. Competitive Insights
Chapter 3. U.S. Glucagon Delivery Devices Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                            3.2.1.1. Growing prevalence of diabetes and hypoglycemia
                            3.2.1.2. Technological advancements
                            3.2.1.3. Aging population
                        3.2.2. Market restraint analysis
                            3.2.2.1. High cost of treatment
                            3.2.2.2. Stringent regulatory approval
                    3.3. U.S. Glucagon Delivery Devices Market Analysis Tools
                        3.3.1. Industry Analysis - Porter’s
                            3.3.1.1. Supplier power
                            3.3.1.2. Buyer power
                            3.3.1.3. Substitution threat
                            3.3.1.4. Threat of new entrant
                            3.3.1.5. Competitive rivalry
                        3.3.2. PESTEL Analysis
                            3.3.2.1. Political landscape
                            3.3.2.2. Technological landscape
                            3.3.2.3. Economic landscape
Chapter 4. U.S. Glucagon Delivery Devices Market: Device Type Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. U.S. Glucagon Delivery Devices Market Movement Analysis
                    4.3. U.S. Glucagon Delivery Devices Market Size & Trend Analysis, by Device Type, 2018 to 2030 (USD Million)
                    4.4. Injectable Devices
                        4.4.1. Injectable devices market estimates and forecasts 2018 to 2030 (USD Million)
                    4.5. Intranasal Devices
                        4.5.1. Intranasal devices market estimates and forecasts 2018 to 2030 (USD Million)
                    4.6. Wearable Devices
                        4.6.1. Wearable devices market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Glucagon Delivery Devices Market: Distribution Channel Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. U.S. Glucagon Delivery Devices Market Movement Analysis
                    5.3. U.S. Glucagon Delivery Devices Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
                    5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                    5.5. Retail Pharmacies
                        5.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
                    5.6. Online Pharmacies
                        5.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
                    5.7. Hospital Pharmacies
                        5.7.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Glucagon Delivery Devices Market: End Use Estimates & Trend Analysis
                    6.1. Segment Dashboard
                    6.2. U.S. Glucagon Delivery Devices End Use Market Movement Analysis
                    6.3. U.S. Glucagon Delivery Devices Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
                    6.4. Hospitals and Clinics
                        6.4.1. Hospitals and clinics market estimates and forecasts 2018 to 2030 (USD Million)
                    6.5. Homecare settings
                        6.5.1. Homecare settings market estimates and forecasts 2018 to 2030 (USD Million)
                    6.6. Other End Users
                        6.6.1. Other end users market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
                    7.1. Recent Developments & Impact Analysis, By Key Market Participants
                    7.2. Company/Competition Categorization
                    7.3. Key company market share analysis, 2023
                    7.4. Company Position Analysis
                    7.5. Company Categorization (Emerging Players, Innovators and Leaders
                    7.6. Company Profiles
                        7.6.1. Eli Lilly and Company
                            7.6.1.1. Company overview
                            7.6.1.2. Financial performance
                            7.6.1.3. Product benchmarking
                            7.6.1.4. Strategic initiatives
                        7.6.2. Novo Nordisk A/S
                            7.6.2.1. Company overview
                            7.6.2.2. Financial performance
                            7.6.2.3. Product benchmarking
                            7.6.2.4. Strategic initiatives
                        7.6.3. Xeris Pharmaceuticals, Inc.
                            7.6.3.1. Company overview
                            7.6.3.2. Financial performance
                            7.6.3.3. Product benchmarking
                            7.6.3.4. Strategic initiatives
                        7.6.4. Boehringer Ingelheim Pharmaceuticals, Inc.
                            7.6.4.1. Company overview
                            7.6.4.2. Financial performance
                            7.6.4.3. Product benchmarking
                            7.6.4.4. Strategic initiatives
                        7.6.5. Tandem Diabetes Care, Inc.
                            7.6.5.1. Company overview
                            7.6.5.2. Financial performance
                            7.6.5.3. Product benchmarking
                            7.6.5.4. Strategic initiatives
                        7.6.6. Fresenius Kabi USA, LLC.
                            7.6.6.1. Company overview
                            7.6.6.2. Financial performance
                            7.6.6.3. Product benchmarking
                            7.6.6.4. Strategic initiatives
                        7.6.7. Zealand Pharma A/S
                            7.6.7.1. Company overview
                            7.6.7.2. Financial performance
                            7.6.7.3. Product benchmarking
                            7.6.7.4. Strategic initiatives
                        7.6.8. Amphastar Pharmaceuticals, Inc.
                            7.6.8.1. Company overview
                            7.6.8.2. Financial performance
                            7.6.8.3. Product benchmarking
                            7.6.8.4. Strategic initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 U.S. glucagon delivery devices market by device type, 2018 - 2030 (USD Million)
Table 4 U.S. glucagon delivery devices market by distribution channel, 2018 - 2030 (USD Million)
Table 5 U.S. glucagon delivery devices market by end use, 2018 - 2030 (USD Million)
Table 6 Participant’s overview
Table 7 Financial performance
Table 8 Key companies undergoing expansions
Table 9 Key companies undergoing acquisitions
Table 10 Key companies undergoing collaborations
Table 11 Key companies launching new products/services
Table 12 Key companies undergoing partnerships
Table 13 Key companies undertaking other strategies

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market summary, 2023 (USD Million)
Fig. 9 Market segmentation & scope
Fig. 10 Market driver impact
Fig. 11 Market restraint impact
Fig. 12 Porter’s analysis
Fig. 13 SWOT analysis
Fig. 14 U.S. glucagon delivery devices market: Device type outlook and key takeaways
Fig. 15 U.S. glucagon delivery devices market: Device type movement analysis
Fig. 16 Injectable devices market, 2018 - 2030 (USD Million)
Fig. 17 Intranasal devices market, 2018 - 2030 (USD Million)
Fig. 18 Wearable devices market, 2018 - 2030 (USD Million)
Fig. 19 U.S. glucagon delivery devices market: Distribution channel outlook and key takeaways
Fig. 20 U.S. glucagon delivery devices market: Distribution channel movement analysis
Fig. 21 Retail pharmacies market, 2018 - 2030 (USD Million)
Fig. 22 Online pharmacies market, 2018 - 2030 (USD Million)
Fig. 23 Hospital pharmacies market, 2018 - 2030 (USD Million)
Fig. 24 U.S. glucagon delivery devices market: End Use outlook and key takeaways
Fig. 25 U.S. glucagon delivery devices market: End Use movement analysis
Fig. 26 Hospitals and clinics market, 2018 - 2030 (USD Million)
Fig. 27 Home care settings market, 2018 - 2030 (USD Million)
Fig. 28 Others market, 2018 - 2030 (USD Million)
Fig. 29 Heat map analysis
Fig. 30 Market participant categorization
Fig. 31 U.S. glucagon delivery devices market share analysis, 2023
Fig. 32 Strategy framework